| Dr Erin Ashley Rellinger, AUD | |
|
3225 Cumberland Blvd Se, Suite 900, Atlanta, GA 30339-6407 | |
| (404) 591-2950 | |
| (404) 591-2949 |
| Full Name | Dr Erin Ashley Rellinger |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 12 Years |
| Location | 3225 Cumberland Blvd Se, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831453612 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AUD003903 (Georgia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Consultants Hearing Aid Center, Llc | 2466737432 | 2 |
News Archive
Universitätsmedizin Berlin and the Berlin Institute of Health are pleased to announce that 'The Virtual Brain' neuroinformatics platform has joined the EU's Flagship 'Human Brain Project'.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.
The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.
With the objective of offering efficient, fast healthcare service with a social focus and at rates everyone can afford, in 2003 the non-profit organization Salud Digna was founded, whose operations became the center of a case study by the School of Business at Harvard University.
› Verified 7 days ago
| Provider Name | Eye Consultants Hearing Aid Center, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1922490119 PECOS PAC ID: 2466737432 Enrollment ID: O20170315000504 |
News Archive
Universitätsmedizin Berlin and the Berlin Institute of Health are pleased to announce that 'The Virtual Brain' neuroinformatics platform has joined the EU's Flagship 'Human Brain Project'.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.
The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.
With the objective of offering efficient, fast healthcare service with a social focus and at rates everyone can afford, in 2003 the non-profit organization Salud Digna was founded, whose operations became the center of a case study by the School of Business at Harvard University.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erin Ashley Rellinger, AUD 3225 Cumberland Blvd Se Ste 900, Atlanta, GA 30339-5971 Ph: (404) 591-2950 | Dr Erin Ashley Rellinger, AUD 3225 Cumberland Blvd Se, Suite 900, Atlanta, GA 30339-6407 Ph: (404) 591-2950 |
News Archive
Universitätsmedizin Berlin and the Berlin Institute of Health are pleased to announce that 'The Virtual Brain' neuroinformatics platform has joined the EU's Flagship 'Human Brain Project'.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.
The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma.
With the objective of offering efficient, fast healthcare service with a social focus and at rates everyone can afford, in 2003 the non-profit organization Salud Digna was founded, whose operations became the center of a case study by the School of Business at Harvard University.
› Verified 7 days ago
Buckhead Ear, Nose And Throat Audiologist Medicare: Medicare Enrolled Practice Location: 1800 Peachtree St Nw, Suite 700, Atlanta, GA 30309 Phone: 404-350-7966 Fax: 404-350-7968 | |
Dr. Debra Burnett Brewer, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 1365 Clifton Rd Ne # A2334, Atlanta, GA 30322 Phone: 404-778-4441 Fax: 404-778-4295 | |
Beftu Teklu, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 5673 Peachtree Dunwoody Rd Ste 150, Atlanta, GA 30342 Phone: 404-297-1785 | |
Margaret Jane Butler, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5461 Meridian Mark Rd Ste 130, Atlanta, GA 30342 Phone: 404-591-1884 | |
Patricia Beatriz Masso Maldonado, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5881 Glenridge Dr Ste 230, Atlanta, GA 30328 Phone: 404-943-0170 | |
Mr. Alan I Segal, M.S. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 960 Johnson Ferry Rd Ne, Ste 200, Atlanta, GA 30342 Phone: 404-943-0900 | |
Kelly Clinkscales Calkins, AU.D Audiologist Medicare: Medicare Enrolled Practice Location: 550 Peachtree St Ne, Ste 1640, Atlanta, GA 30308 Phone: 404-653-0830 Fax: 404-653-0832 |